Sulcoflex: a new IOL concept for the pseudophakic eye

Article

The new sulcoflex intraocular lens (IOL), which has been designed for sulcus-implantation in the pseudophakic eye ("piggy back"), is safe and well-tolerated.

The new sulcoflex intraocular lens (IOL), which has been designed for sulcus-implantation in the pseudophakic eye ("piggy back"), is safe and well-tolerated, according to Michael Amon, MD from the University of Vienna Medical School, Austria.

Dr Amon and colleagues worked in collaboration with UK firm Rayner to develop the sulcoflex lens, in response to current demand for this lens type. According to Dr Amon, patient expectations for an excellent refractive result following cataract surgery or refractive lens exchange (RLE) are growing. Furthermore, surgeons often want to avoid IOL exchange at all costs, hence the implantation of a pseudophakic lens is appealing.

The new lens is made of Rayner's patented Rayacryl material (hydrophilic acrylic). It is a single-piece, 6.5 mm diameter, implant with round optic- and haptic-edges and a concave posterior optic surface. The angulated haptic has an undulated design to preclude IOL rotation.

Dr Amon presented results from a pilot study, which included six eyes (two eyes received a multifocal IOL after Prelex and four eyes received YAG capsulotomy prior to sulcoflex implantation through a 3.0 mm clear corneal incision). The mean age of patients was 55 years, pre-implantation ametropia range was +2 D/-2 D and follow-up results at four months were collected.

Four-month postoperative refraction was ±0.25 D, intraocular pressure (IOP) ranged from 11 to 22 mmHg and correct positioning of the lens was achieved in 100% of patients, with no evidence of tilt or rotation.

At the study's conclusion, Dr Amon confirmed that the sulcoflex lens is well-tolerated and he suggested correction of postoperative ametropia, astigmatism (toric IOL), paediatric cataract and aphakia as possible indications for the lens.

He summed up by saying that implantation of the sulcoflex IOL is safe, easy and is less traumatic than IOL exchange. According to Dr Amon, postoperative refraction is stable with good predictability and rotation stability. As a result, he feels that the sulcoflex lens represents a promising, new IOL concept for a number of indications.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.